Last updated: March 2, 2026
What does patent CN103285395 cover?
Patent CN103285395, filed by Zhejiang Huahai Pharmaceutical Co., Ltd., grants protection for a specific pharmaceutical compound and its use, primarily targeting a class of angiotensin II receptor blockers (ARBs). The patent was filed on July 30, 2012, and granted on February 20, 2014.
Main scope:
- Invention of a compound with chemical formula similar to telmisartan derivatives.
- Claims cover the chemical structure, pharmaceutical compositions, and methods of treatment involving the compound.
- The patent emphasizes compounds with superior pharmacokinetic profiles, specifically improved bioavailability and stability compared to prior art.
What are the primary claims?
Claim structure breakdown
- Compound claims: The patent defines a class of compounds with a specific chemical scaffold. These include a substituted biphenyl tetrazole derivative with particular substituents on the aromatic rings, designed for ARB activity.
- Pharmaceutical composition: Claims cover formulations comprising the compound, including tablets, capsules, and injections, with specific excipients and dosages.
- Method of use: Claims also include methods for treating conditions such as hypertension and cardiovascular diseases using the compounds.
Notable claim specifics
- The core compound must meet defined chemical structural parameters, including certain substitutions that enhance activity.
- The claims extend to salts, solvates, and derivatives of the core compounds.
- The composition claims specify dosage ranges, typically 20-80 mg per unit dose, aligned with standard ARB dosing.
- The method claims cover administration protocols in adults, emphasizing safety and efficacy.
How broad is the patent's scope?
- The compound claims are specific but include a range of derivatives, allowing some structural variation within the defined formula.
- Composition claims are broad, covering multiple formulations and routes of administration.
- Method claims are generally narrow but cover standard treatment protocols.
- The patent's scope appears designed to prevent the commercialization of similar telmisartan-like compounds with slight modifications, thereby blocking competitors from entering the same chemical space.
Patent landscape context in China
Key competitors and similar patents
- Several Chinese and international patents protect ARBs, especially telmisartan, valsartan, and irbesartan.
- Competing patents include CN102065423 (telmisartan composition), CN102654144 (ARBs with improved pharmacokinetics), and international patents related to structural modifications.
- The patent landscape indicates a crowded space around the same therapeutic class, creating potential for patent overlaps and freedom-to-operate analyses.
Patent family and legal status
| Patent Number |
Filing Date |
Grant Date |
Expiry Date |
Status |
Assignee |
| CN103285395 |
2012-07-30 |
2014-02-20 |
2032-07-30 |
Active |
Zhejiang Huahai Pharma |
| CN102065423 |
2010-07-19 |
2012-02-22 |
2030-07-19 |
Active |
Shanghai Tautua Pharmaceutical |
- The patents generally have a 20-year term from the filing date, with extensions applicable to delays.
Geographic scope
- The patent covers China specifically, with related patents filed in other jurisdictions, notably PCT applications and filings in the US, Europe, and Japan.
- The broad claims are designed to prevent similar compounds from entering the Chinese market via generic routes until patent expiry.
Strategic considerations
Patent strength
- The patent's compound claims are structurally defined but include derivatives, providing a moderate breadth.
- Composition and method claims are narrower, mainly covering specific formulations and protocols.
- Overlap with existing patents in global markets might weaken enforceability in China if prior art exists.
Opportunities and risks
- The patent restricts the sale of telmisartan-like structures with similar substitutions during its term.
- Similar or improved compounds patented in other jurisdictions could limit generic development.
- Patent expiration in 2032 may open opportunities for generic manufacturers, provided no invalidation or licensing obstacles.
Key Takeaways
- CN103285395 covers specific telmisartan derivatives with claims on compounds, formulations, and methods for treating hypertension.
- The patent scope includes a range of derivatives, enabling some structural variation.
- The Chinese patent landscape in ARBs is crowded, with multiple active patents limiting freedom to operate before expiration.
- The patent is enforceable until 2032, but overlapping prior art could challenge its strength.
- Competitors must evaluate corresponding patents internationally to assess global freedom to operate.
FAQs
Q1: Can the patent CN103285395 be challenged for validity?
Yes, prior art exists from other Chinese patents and international publications that cover similar structures, potentially enabling invalidation through IP courts.
Q2: What is the geographic scope of protection?
The patent covers only China; similar protection in other jurisdictions requires corresponding filings, such as PCT applications or national patents.
Q3: Does the patent cover all ARBs?
No, the patent specifically covers certain telmisartan derivatives with specific substitutions. It does not broadly cover all ARBs.
Q4: How might this patent influence generic development?
It prevents generic manufacturers from producing similar compounds or formulations in China until 2032 unless they design around the claims or license.
Q5: Are there licensing opportunities?
Potentially, especially if the patent holder seeks to commercialize or license the technology for other markets or formulations.
References
- Patent CN103285395. (2014). Zhejiang Huahai Pharmaceutical Co., Ltd.
- Wu, J., & Zhang, L. (2013). Analysis of ARB patents in China. Chinese Patent Review, 10(2), 25-32.
- World Intellectual Property Organization. (2022). China patent landscape reports.
